Literature DB >> 24074616

Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients.

Yan-yan Chen, Liu-bo Wang, Hui-li Zhu, Xiang-yang Li, Yan-ping Zhu, Yu-lei Yin, Fan-zhen Lü, Zi-li Wang, Jie-ming Qu.   

Abstract

OBJECTIVE: To evaluate the correlation between programmed death-ligand 1 (PD-L1) expression in primary lung cancer cells, tumor associated macrophages (TAM) and patients' clinicopathological characteristics.
METHODS: From 2008 to 2010, 208 non-small cell lung cancer patients who underwent surgery or CT-guided biopsy were recruited from Huadong Hospital, Fudan University. Immunohistochemistry staining was performed to evaluate the PD-L1 expression in both primary lung cancer cells and CD68 positive TAM. The relationship between PD-L1 expression and the clinical pathology was evaluated using χ(2) test. Spearman's rank correlations were used to determine the correlation between PD-L1 expression in tumor cells and macrophages.
RESULTS: Positive PD-L1 expression in primary cancer cells was found in 136 (65.3%) patients, which were negatively correlated with lymph node metastasis (P=0.009) and smoking history (P=0.036). Besides, TAM with PD-L1 expression (found in 116 patients) was positively associated with smoking history (P=0.034), well-differentiation (P=0.029) and negative lymph node metastasis (P=0.0096). A correlation between PD-L1 expression in primary tumor cells and non-small cell lung cancer associated macrophages was found (r=0.228, P=0.021).
CONCLUSION: PD-L1, secreted from TAM, might induce cancer cells apoptosis, and decrease lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24074616     DOI: 10.1016/s1001-9294(13)60040-1

Source DB:  PubMed          Journal:  Chin Med Sci J        ISSN: 1001-9294


  17 in total

Review 1.  Nivolumab in NSCLC: latest evidence and clinical potential.

Authors:  Raghav Sundar; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

2.  Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Zhen-Kui Pan; Feng Ye; Xuan Wu; Han-Xiang An; Jing-Xun Wu
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

3.  A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.

Authors:  Jin Li; Yaoqi Chen; Xiaoshun Shi; Xiaobing Le; Fenglan Feng; Jingyi Chen; Chengzhi Zhou; Yusong Chen; Shuai Wen; Haikang Zeng; Allen M Chen; Yu Zhang
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

4.  Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.

Authors:  Shaodong Hong; Nan Chen; Wenfeng Fang; Jianhua Zhan; Qing Liu; Shiyang Kang; Xiaobo He; Lin Liu; Ting Zhou; Jiaxing Huang; Ying Chen; Tao Qin; Yaxiong Zhang; Yuxiang Ma; Yunpeng Yang; Yuanyuan Zhao; Yan Huang; Li Zhang
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

5.  A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.

Authors:  Xiao-Yan Hu; Wei Zhang; Yue Hu; Yong Zhang; Rui Gong; Jin-Yan Liang; Li Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05

Review 6.  Immunotherapy in the treatment of non-small cell lung cancer.

Authors:  Raghav Sundar; Richie Soong; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Lung Cancer       Date:  2014-05-14       Impact factor: 5.705

7.  PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

Authors:  Lars Henning Schmidt; Andreas Kümmel; Dennis Görlich; Michael Mohr; Sebastian Bröckling; Jan Henrik Mikesch; Inga Grünewald; Alessandro Marra; Anne M Schultheis; Eva Wardelmann; Carsten Müller-Tidow; Tilmann Spieker; Christoph Schliemann; Wolfgang E Berdel; Rainer Wiewrodt; Wolfgang Hartmann
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

8.  The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.

Authors:  Yanna Tang; Wenfeng Fang; Yaxiong Zhang; Shaodong Hong; Shiyang Kang; Yue Yan; Nan Chen; Jianhua Zhan; Xiaobo He; Tao Qin; Ge Li; Wenyi Tang; Peijian Peng; Li Zhang
Journal:  Oncotarget       Date:  2015-06-10

Review 9.  Advances in immunotherapy for treatment of lung cancer.

Authors:  Jean G Bustamante Alvarez; María González-Cao; Niki Karachaliou; Mariacarmela Santarpia; Santiago Viteri; Cristina Teixidó; Rafael Rosell
Journal:  Cancer Biol Med       Date:  2015-09       Impact factor: 4.248

Review 10.  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Authors:  Weijie Ma; Barbara M Gilligan; Jianda Yuan; Tianhong Li
Journal:  J Hematol Oncol       Date:  2016-05-27       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.